The global sepsis diagnostics market in terms of revenue was estimated to be worth $503 million in 2021 and is poised to reach $771 million by 2026, growing at a CAGR of 8.9% from 2021 to 2026. The new research study consists of an industry trend analysis of the market.

The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

The demand for sepsis diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for sepsis diagnostic research activities, the growing burden of infectious diseases, the rising number of sepsis incidences, and growing government initiatives for creating sepsis awareness. 

Sepsis is a very difficult condition to diagnose and the risk of mortality increases by 7.6% with a delay of even 1 minute in antibiotic administration in septic shock patients with hypertension.

Thus, increasing the need for the rapid diagnosis of sepsis to reduce the delay of antibiotic therapy among patients with sepsis. Many sepsis diagnostic manufacturers are expanding their product offering in point of care technology rapidly detecting the sepsis, reducing the overall turnaround time of diagnosis. 

Browse and in-depth TOC on "Sepsis Diagnostics Market"
201- Tables
47- Figures
236- Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155

Based on technology, the global sepsis diagnostic market is segmented into microbiology, molecular diagnostics, immunoassay, flow cytometry, microfluidics, and biomarkers. The biomarkers segment is expected to grow at the highest CAGR during the forecast period. Biomarkers offer various advantages in the diagnosis of sepsis as they help identify and differentiate bacterial infection from fungal infection and provide early intervention of disease diagnosis. Moreover, the ongoing research on the novel biomarkers for the early diagnosis of sepsis.

Based on products, the global sepsis diagnostics market is segmented into blood culture media, assays & reagents, instruments, and software. The blood culture media segment is expected to grow at the highest CAGR during the forecast period owing to the increased used of blood culture media as it is the standard method for diagnosis of sepsis across the globe.

Geographical Growth Scenario:

Geographically, the sepsis diagnostic market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to account for the largest share of the market. This can be attributed to the growing prevalence of sepsis, increasing incidence of hospital-acquired infections, fast adoption of high-end sepsis diagnostics devices, and rising government support for sepsis-related research.

Key Players:

Some of the prominent players in the sepsis diagnostics market are bioMérieux (France), Becton Dickinson Company (US), Danaher (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland). Other players include T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), among others.